LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV)

Inclusion Criteria: * Patients with HIV infection diagnosed with DLBCL in any stage (I-IV according to the Ann Arbor classification) not previously treated for the lymphoma. * Patients with CD20-positive diffuse large B-cell lymphoma * Aged from 18 to 70 years old * Any score of International Prognostic Index. (It is also applicable in patients with non-Hodgkin lymphoma \[NHL\] infected with HIV.) * ECOG performance status 0 to 3 * Written informed consent * Absolute neutrophil count \> 1.5 x 10\^9/L. * Absence of synchronic or non-synchronic neoplasia with the exception of non-melanoma skin tumors or in situ cervical carcinoma. * CD4+ lymphocyte count \> 100/µL Exclusion Criteria: * Patients with diffuse large B cell lymphoma previously treated. * Patients with primary central nervous system lymphoma. * Patients with Burkitt or Burkitt-like NHL. * CD4+ lymphocyte count \< 100/µL * Opportunistic infections or other AIDS-related neoplasias in activity. * Active drug-addiction. * Pregnant or lactating women or adults of fertile age who do not use an effective contraceptive method. * Patients with serious altered renal function (creatinine \> 2.5 x upper limit of normal \[ULN\]) or hepatic \[bilirubin, ALT or AST \> 2.5 x ULN\], except if the investigators suspect that they are caused by the disease. * Cardiac insufficiency with ejection fraction \< 40% * Patients with serious psychiatric diseases that can interfere with their capacity to understand the study (including alcoholism or active drug-addiction). * ECOG \> 3 * Patients with a known hypersensitivity to murine proteins or any other component of the study drugs.